Cellectis gets US ok to test its universal donor derived cancer cell therapy
US regulators have cleared French biotech Cellectis to trial its “off-the-shelf” blood cancer cell therapy, UCART123.
Archives for February 8, 2017
Catalent running its biologics business at over 90% capacity
Catalent is struggling to keep up with demand for its biomanufacturing services, but a third production train will open up more capacity from October.
German affinity chromatography tech firm changes hands, changes name
German private equity firm UV-Cap GmbH has bought Scil Proteins and renamed the affinity chromatography tech company Navigo Proteins.